[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:lung-non-small-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":399},"Lung Non-Small Cell Carcinoma",711,628,[8,16,22,29,36,43,50,56,62,68,74,80,86,92,98,104,110,116,122,128,134,140,146,152,158,163,169,175,181,187,193,199,205,211,217,223,229,235,240,245,250,256,262,268,274,280,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07252739","KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J\u002FKEYMAKER-U01J)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:09.452956Z","2026-07-30T01:46:14.436674Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07017829","GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer",[12],"2026-08-26T02:17:28.381459Z","2026-07-30T01:46:14.416741Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07286149","A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.895684Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05142189","Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",[33],"Phase 1","2026-08-26T02:16:32.589113Z","2026-07-24T01:27:14.869513Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT04928846","A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",[40],"Phase 3","2026-08-26T02:19:19.975067Z","2026-07-19T19:36:05.115045Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":48,"content_modified":49},"NCT07155187","A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",[47],"Phase 2\u002FPhase 3","2026-08-26T02:17:30.145302Z","2026-07-19T19:36:05.063102Z",{"nct_id":51,"title":52,"phases":53,"status":13,"updated_at":54,"content_modified":55},"NCT06890598","Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer",[40],"2026-08-26T02:19:13.549512Z","2026-07-19T19:36:05.058056Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06627647","A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC",[40],"2026-08-26T02:17:45.190188Z","2026-07-19T19:36:05.037548Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT05742607","IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)",[12],"2026-08-26T02:16:46.147215Z","2026-07-05T05:32:16.816670Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT05802186","Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study",[],"2026-08-26T02:16:16.995720Z","2026-07-05T05:32:16.812430Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05443126","A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies",[26],"2026-08-26T02:16:33.772093Z","2026-07-05T05:32:16.803701Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT05136846","Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer",[33],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.797971Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT06312137","A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)",[40],"2026-08-26T02:19:02.550788Z","2026-07-05T05:32:16.749560Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06225427","Gilteritinib for the Treatment of ALK NSCLC",[33],"2026-08-26T02:17:57.117858Z","2026-07-05T05:32:16.747900Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06130553","A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced\u002FMetastatic Solid Tumors",[26],"2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.744919Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07140016","A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)",[33],"2026-08-26T02:17:04.346841Z","2026-07-05T05:32:16.736027Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06899126","Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",[40],"2026-08-26T02:18:58.141497Z","2026-07-05T05:32:16.701037Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT07566052","A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation",[40],"2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.686769Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07355205","First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer",[26],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.677180Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT05098132","Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers",[26],"2026-08-26T02:18:17.007929Z","2026-07-05T03:45:20.449302Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07680764","A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:18:11.042248Z","2026-07-05T03:45:20.444006Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07660094","Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)",[40],"2026-08-26T02:17:16.126291Z","2026-07-05T03:45:20.258994Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT07388524","Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial",[40],"2026-08-26T02:17:57.997171Z","2026-07-05T03:45:20.251331Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT05384626","A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)",[26],"2026-08-26T02:15:43.339060Z","2026-06-17T19:21:16.597610Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":78,"content_modified":162},"NCT07293247","A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment",[12],"2026-06-17T02:29:30.055742Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06567015","Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs",[26],"2026-08-26T02:15:26.669629Z","2026-06-16T05:54:07.919816Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:16:08.402952Z","2026-06-16T05:54:07.906610Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT04613596","Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7",[47],"2026-08-26T02:16:20.336282Z","2026-06-16T05:54:07.905720Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07619599","A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab",[33],"2026-08-26T02:19:09.651016Z","2026-06-04T01:30:07.904532Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT07619339","A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer",[33],"2026-08-26T02:15:18.897219Z","2026-06-04T01:30:07.903453Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07554339","A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015\u002FKANDLELIT-015)",[40],"2026-08-26T02:15:44.309045Z","2026-06-04T01:30:07.902092Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT07603856","A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer",[12],"2026-08-26T02:18:03.638950Z","2026-05-29T15:36:40.222379Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT07594522","A Study of Ivonescimab in People With Non-Small Cell Lung Cancer",[26],"2026-08-26T02:17:47.813245Z","2026-05-29T15:36:40.204393Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT07513376","A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)",[40],"2026-08-26T02:18:42.501841Z","2026-05-29T15:36:40.190137Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT07365319","A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.",[47],"2026-08-26T02:16:21.385056Z","2026-05-29T15:36:40.186744Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06741085","A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain",[12],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:29.731134Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06449313","Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement",[12],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.726652Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":203,"content_modified":239},"NCT06275360","Repositioning Immunotherapy in VetArans With Lung Cancer",[12],"2026-05-05T02:43:29.714483Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":203,"content_modified":244},"NCT07361510","A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)",[40],"2026-05-05T02:43:29.714186Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":203,"content_modified":249},"NCT05589818","Pembrolizumab for Advanced NSCLC and PS 2-3",[12],"2026-05-05T02:43:29.712457Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT02133196","T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer",[12],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:29.705357Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":260,"content_modified":261},"NCT06905197","A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)",[33],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:29.704459Z",{"nct_id":263,"title":264,"phases":265,"status":13,"updated_at":266,"content_modified":267},"NCT02468024","JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer",[40],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:29.703457Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT06772623","Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations",[26],"2026-08-26T02:15:30.699880Z","2026-05-05T02:43:29.702001Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT07100080","Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)",[47],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:29.701167Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT06793215","A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",[40],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.700315Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT04614103","Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.683145Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06249282","Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer",[33],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:29.680313Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT06996782","A Platform Study in Non-Small Cell Lung Cancer (NSCLC)",[26],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.675856Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT07116057","MOv19-BBz CAR T Cells in FRa+ Cancers",[33],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.675266Z",[311,315,319,323,327,331,335,339,343,347,350,354,358,362,365,369,372,376,379,382,385,389,392,396],{"biomarker":312,"count":313,"slug":314},"Programmed Cell Death 1 Ligand 1",63,"programmed-cell-death-1-ligand-1",{"biomarker":316,"count":317,"slug":318},"GTPase KRas",59,"gtpase-kras",{"biomarker":320,"count":321,"slug":322},"Soluble Epidermal Growth Factor Receptor",54,"soluble-epidermal-growth-factor-receptor",{"biomarker":324,"count":325,"slug":326},"MSI1 Gene",23,"msi1-gene",{"biomarker":328,"count":329,"slug":330},"ERBB2 Gene",20,"erbb2-gene",{"biomarker":332,"count":333,"slug":334},"ALK Gene",19,"alk-gene",{"biomarker":336,"count":337,"slug":338},"ROS1 Gene",16,"ros1-gene",{"biomarker":340,"count":341,"slug":342},"MTAP Gene",14,"mtap-gene",{"biomarker":344,"count":345,"slug":346},"BRAF Gene",13,"braf-gene",{"biomarker":348,"count":345,"slug":349},"MET Gene","met-gene",{"biomarker":351,"count":352,"slug":353},"MRC1 wt Allele",12,"mrc1-wt-allele",{"biomarker":355,"count":356,"slug":357},"Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret",10,"proto-oncogene-tyrosine-protein-kinase-receptor-ret",{"biomarker":359,"count":360,"slug":361},"RAS Family Oncogene",7,"ras-family-oncogene",{"biomarker":363,"count":360,"slug":364},"TPM2 wt Allele","tpm2-wt-allele",{"biomarker":366,"count":367,"slug":368},"NTRK Family Gene",6,"ntrk-family-gene",{"biomarker":370,"count":367,"slug":371},"Programmed Cell Death Protein 1","programmed-cell-death-protein-1",{"biomarker":373,"count":374,"slug":375},"HLA-A Gene",5,"hla-a-gene",{"biomarker":377,"count":374,"slug":378},"HLA Class I Histocompatibility Antigen, A-2 Alpha Chain","hla-class-i-histocompatibility-antigen-a-2-alpha-chain",{"biomarker":380,"count":374,"slug":381},"NRAS Gene","nras-gene",{"biomarker":383,"count":374,"slug":384},"STK11 Gene","stk11-gene",{"biomarker":386,"count":387,"slug":388},"HIV Infection",4,"hiv-infection",{"biomarker":390,"count":387,"slug":391},"TACSTD2 wt Allele","tacstd2-wt-allele",{"biomarker":393,"count":394,"slug":395},"BRCA1 Gene",3,"brca1-gene",{"biomarker":397,"count":394,"slug":398},"CD276 wt Allele","cd276-wt-allele",[400,404,408,412,416,420,424,428,432,436,440,444,448,452,456,460,464,468,472,476,480,484,488,492],{"state":401,"count":402,"slug":403},"Texas",356,"texas",{"state":405,"count":406,"slug":407},"California",331,"california",{"state":409,"count":410,"slug":411},"New York",297,"new-york",{"state":413,"count":414,"slug":415},"Florida",245,"florida",{"state":417,"count":418,"slug":419},"Virginia",221,"virginia",{"state":421,"count":422,"slug":423},"Ohio",199,"ohio",{"state":425,"count":426,"slug":427},"Tennessee",194,"tennessee",{"state":429,"count":430,"slug":431},"Michigan",180,"michigan",{"state":433,"count":434,"slug":435},"Massachusetts",175,"massachusetts",{"state":437,"count":438,"slug":439},"Pennsylvania",170,"pennsylvania",{"state":441,"count":442,"slug":443},"Illinois",148,"illinois",{"state":445,"count":446,"slug":447},"New Jersey",144,"new-jersey",{"state":449,"count":450,"slug":451},"Washington",136,"washington",{"state":453,"count":454,"slug":455},"Missouri",129,"missouri",{"state":457,"count":458,"slug":459},"North Carolina",128,"north-carolina",{"state":461,"count":462,"slug":463},"Maryland",127,"maryland",{"state":465,"count":466,"slug":467},"Colorado",125,"colorado",{"state":469,"count":470,"slug":471},"Minnesota",108,"minnesota",{"state":473,"count":474,"slug":475},"Arizona",104,"arizona",{"state":477,"count":478,"slug":479},"Georgia",100,"georgia",{"state":481,"count":482,"slug":483},"Oregon",91,"oregon",{"state":485,"count":486,"slug":487},"Connecticut",84,"connecticut",{"state":489,"count":490,"slug":491},"Kentucky",81,"kentucky",{"state":493,"count":490,"slug":494},"Utah","utah"]